Mechanism of EBV inducing anti-tumour immunity and its therapeutic use
Il-Kyu Choi, Zhe Wang, Qiang Ke, Min Hong, Dereck W Paul Jr, Stacey M Fernandes, Zhuting Hu, Jonathan Stevens, Indira Guleria, Hye-Jung Kim, Harvey Cantor, Kai W Wucherpfennig, Jennifer R Brown, Jerome Ritz, Baochun Zhang, Il-Kyu Choi, Zhe Wang, Qiang Ke, Min Hong, Dereck W Paul Jr, Stacey M Fernandes, Zhuting Hu, Jonathan Stevens, Indira Guleria, Hye-Jung Kim, Harvey Cantor, Kai W Wucherpfennig, Jennifer R Brown, Jerome Ritz, Baochun Zhang
Abstract
Tumour-associated antigens (TAAs) comprise a large set of non-mutated cellular antigens recognized by T cells in human and murine cancers. Their potential as targets for immunotherapy has been explored for more than two decades1, yet the origins of TAA-specific T cells remain unclear. While tumour cells may be an important source of TAAs for T cell priming2, several recent studies suggest that infection with some viruses, including Epstein-Barr virus and influenza virus can elicit T cell responses against abnormally expressed cellular antigens that function as TAAs3,4. However, the cellular and molecular basis of such responses remains undefined. Here we show that expression of the Epstein-Barr virus signalling protein LMP1 in B cells provokes T cell responses to multiple TAAs. LMP1 signalling leads to overexpression of many cellular antigens previously shown to be TAAs, their presentation on major histocompatibility complex classes I (MHC-I) and II (MHC-II) (mainly through the endogenous pathway) and the upregulation of costimulatory ligands CD70 and OX40L, thereby inducing potent cytotoxic CD4+ and CD8+ T cell responses. These findings delineate a mechanism of infection-induced anti-tumour immunity. Furthermore, by ectopically expressing LMP1 in tumour B cells from patients with cancer and thereby enabling them to prime T cells, we develop a general approach for rapid production of autologous cytotoxic CD4+ T cells against a wide range of endogenous tumour antigens, such as TAAs and neoantigens, for treating B cell malignancies. This work stresses the need to revisit classical concepts concerning viral and tumour immunity, which will be critical to fully understand the impact of common infections on human health and to improve the rational design of immune approaches to treatment of cancers.
Conflict of interest statement
The authors declare competing financial interests: I.K.C., Z.W. and B.Z. are inventors on patent applications which cover parts of this work; Z.H. is a current employee of ElevateBio.
Figures
References
- Coulie PG, Van den Eynde BJ, van der Bruggen P & Boon T Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature reviews. Cancer 14, 135–146, doi:10.1038/nrc3670 (2014).
- Blankenstein T, Coulie PG, Gilboa E & Jaffee EM The determinants of tumour immunogenicity. Nature reviews. Cancer 12, 307–313, doi:10.1038/nrc3246 (2012).
- Long HM et al. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells. Blood 114, 807–815, doi:10.1182/blood-2008-12-194043 (2009).
- Iheagwara UK et al. Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance. Cancer immunology research 2, 263–273, doi:10.1158/2326-6066.CIR-13-0125 (2014).
- Taylor GS, Long HM, Brooks JM, Rickinson AB & Hislop AD The immunology of Epstein-Barr virus-induced disease. Annual review of immunology 33, 787–821, doi:10.1146/annurev-immunol-032414-112326 (2015).
- Zhang B et al. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 148, 739–751, doi:10.1016/j.cell.2011.12.031 (2012).
- Yasuda T et al. Studying Epstein-Barr Virus Pathologies and Immune Surveillance by Reconstructing EBV Infection in Mice. Cold Spring Harbor symposia on quantitative biology, doi:10.1101/sqb.2013.78.020222 (2013).
- Pearce EL et al. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302, 1041–1043, doi:10.1126/science.1090148 (2003).
- Choi IK et al. Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4(+) and CD8(+) T cell responses. Proceedings of the National Academy of Sciences of the United States of America 115, E686–E695, doi:10.1073/pnas.1713607115 (2018).
- Smith C et al. Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. Blood 113, 6148–6152, doi:10.1182/blood-2009-02-203687 (2009).
- Acha-Orbea H & MacDonald HR Superantigens of mouse mammary tumor virus. Annual review of immunology 13, 459–486, doi:10.1146/annurev.iy.13.040195.002331 (1995).
- Thorley-Lawson DA Epstein-Barr virus: exploiting the immune system. Nature reviews. Immunology 1, 75–82, doi:10.1038/35095584 (2001).
- Schultze JL et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proceedings of the National Academy of Sciences of the United States of America 92, 8200–8204 (1995).
- Kaye KM, Izumi KM & Kieff E Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the United States of America 90, 9150–9154 (1993).
- Muranski P et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362–373, doi:10.1182/blood-2007-11-120998 (2008).
- Brooks A et al. Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme. Proceedings of the National Academy of Sciences of the United States of America 88, 3290–3294, doi:10.1073/pnas.88.8.3290 (1991).
- Dengjel J et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proceedings of the National Academy of Sciences of the United States of America 102, 7922–7927, doi:10.1073/pnas.0501190102 (2005).
- Paludan C et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307, 593–596, doi:10.1126/science.1104904 (2005).
- Challa-Malladi M et al. Combined genetic inactivation of beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer cell 20, 728–740, doi:10.1016/j.ccr.2011.11.006 (2011).
- Roemer MGM et al. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 36, 942–950, doi:10.1200/JCO.2017.77.3994 (2018).
- Elpek KG, Lacelle C, Singh NP, Yolcu ES & Shirwan H CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. Journal of immunology 178, 6840–6848, doi:10.4049/jimmunol.178.11.6840 (2007).
- Kowalewski DJ et al. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America 112, E166–175, doi:10.1073/pnas.1416389112 (2015).
- Bollard CM et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32, 798–808, doi:10.1200/JCO.2013.51.5304 (2014).
- Jayasooriya S et al. Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children. PLoS pathogens 11, e1004746, doi:10.1371/journal.ppat.1004746 (2015).
- Dunmire SK, Grimm JM, Schmeling DO, Balfour HH Jr. & Hogquist KA The Incubation Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events. PLoS pathogens 11, e1005286, doi:10.1371/journal.ppat.1005286 (2015).
- Haabeth OA et al. How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Frontiers in immunology 5, 174, doi:10.3389/fimmu.2014.00174 (2014).
- Zhang B et al. An oncogenic role for alternative NF-kappaB signaling in DLBCL revealed upon deregulated BCL6 expression. Cell Rep 11, 715–726, doi:10.1016/j.celrep.2015.03.059 (2015).
- Koralov SB et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 132, 860–874, doi:10.1016/j.cell.2008.02.020 (2008).
- He L et al. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. J Immunol Methods 304, 43–59, doi:10.1016/j.jim.2005.06.005 (2005).
- Cui Y et al. Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL. Blood 125, 2958–2967, doi:10.1182/blood-2014-10-609271 (2015).
- Yamaguchi S et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 110, 1469–1477, doi:10.1002/cncr.22958 (2007).
- Porichis F et al. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. Journal of virology 88, 2508–2518, doi:10.1128/JVI.02034-13 (2014).
Source: PubMed